OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26

Rhea-AI Summary

OPKO Health (NASDAQ: OPK) will report operating and financial results for the three and 12 months ended December 31, 2025, after U.S. markets close on February 26, 2026.

Senior management will host a business update, discuss results and provide financial guidance on a conference call and live webcast at 4:30 p.m. ET. Registration, dial-in numbers, webcast links and replay details are available for investors; telephone replay accessible through March 5, 2026.

News Market Reaction – OPK

-3.20%

1 alert

-3.20% News Effect

On the day this news was published, OPK declined 3.20%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Earnings report date: February 26, 2026 Quarter end date: December 31, 2025 Conference call time: 4:30 p.m. ET +5 more

8 metrics

Earnings report date February 26, 2026 Planned Q4 and full-year 2025 results release after market close

Quarter end date December 31, 2025 Three- and 12-month period to be reported

Conference call time 4:30 p.m. ET Start time for earnings call and webcast

Telephone replay end March 5, 2026 Date until which telephone replay is available

U.S. dial-in 833-630-0584 Domestic participant number for live conference call

International dial-in 412-317-1815 International participant number for live conference call

Replay U.S. dial-in 855-669-9658 Domestic number for telephone replay

Replay passcode 2367034 Passcode required to access telephone replay

Market Reality Check

Price: $1.17 Vol: Volume 1,564,021 is below...

low vol

$1.17 Last Close

Volume Volume 1,564,021 is below 20-day average 3,306,424 (relative volume 0.47x) ahead of the earnings call. low

Technical Shares at $1.25 are trading below the $1.36 200-day moving average and 38.57% under the 52-week high.

Peers on Argus

Peers show mixed, generally modest moves, with one key peer slightly positive an...

Peers show mixed, generally modest moves, with one key peer slightly positive and others negative, suggesting today’s 2.46% gain in OPK is more company-specific than sector-driven.

Historical Context

5 past events · Latest: Feb 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 04	Partnership expansion	Positive	-0.8%	Expanded Entera Bio partnership on oral long-acting PTH and OXM programs.
Jan 06	Conference participation	Neutral	+3.0%	Participation in J.P. Morgan Healthcare Conference and investor meetings.
Nov 19	Conference participation	Neutral	-0.8%	Participation in Piper Sandler Healthcare Conference with investor meetings.
Oct 29	Earnings report	Positive	+2.1%	Q3 2025 results, asset sale to Labcorp, and collaboration with Regeneron.
Oct 29	Research collaboration	Positive	-0.7%	ModeX-Regeneron multispecific antibody collaboration announcement.

Pattern Detected

Recent news has produced mixed reactions: partnerships sometimes saw negative moves, while earnings and conference participation often aligned with modest gains.

Recent Company History

Over the last several months, OPKO has combined strategic deals, portfolio reshaping and investor outreach. On Oct 29, 2025, it reported Q3 2025 earnings and business highlights, including the sale of BioReference oncology assets and a large collaboration with Regeneron, with shares rising 2.1%. Partnership announcements on Oct 29, 2025 and Feb 4, 2026 produced slightly negative moves. Conference participation in late 2025 and early 2026 generated small, mixed reactions. Today’s earnings date notice fits this pattern of event-driven but generally moderate stock responses.

Market Pulse Summary

This announcement sets the timetable for OPKO’s fourth quarter and full-year 2025 results, with a ca...

Analysis

This announcement sets the timetable for OPKO’s fourth quarter and full-year 2025 results, with a call on February 26, 2026 to provide a business update and guidance. In recent quarters, the company reported profitability aided by asset sales and pursued collaborations and portfolio adjustments. Investors may focus on how upcoming results build on those actions, including revenue trends, profitability, and capital allocation, and how management’s guidance frames the next phase of the company’s strategy.

AI-generated analysis. Not financial advice.

MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on Thursday, February 26, 2026. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast beginning at 4:30 p.m. Eastern time.

CONFERENCE CALL & WEBCAST INFORMATION

OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast of the call can also be accessed at OPKO’s Investor Relations page and here.

A telephone replay will be available until March 5, 2026, by dialing 855-669-9658 (U.S.) or 412-317-0088 (International) and providing the passcode 2367034. A webcast replay will be available beginning approximately one hour after the completion of the live conference call here.

About OPKO Health

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.

Contacts:

Alliance Advisors IR
Yvonne Briggs, 310-691-7100
ybriggs@allianceadvisors.com
or
Bruce Voss, 310-691-7100
bvoss@allianceadvisors.com

FAQ

When will OPKO (OPK) report Q4 2025 results and what time is the conference call?

OPKO will report results after market close on February 26, 2026, with a conference call at 4:30 p.m. ET. According to the company, senior management will provide a business update, discuss results and give financial guidance during the webcast and call.

How can investors join the OPKO (OPK) February 26, 2026 earnings call and webcast?

Investors may pre-register for the call to receive a PIN or dial 833-630-0584 (U.S.) or 412-317-1815 (International). According to the company, a live audio webcast will also be available on OPKO’s Investor Relations page.

Will OPKO (OPK) provide a replay of the February 26, 2026 earnings call and for how long?

A telephone replay will be available until March 5, 2026 and a webcast replay will be posted about one hour after the call. According to the company, replay dial-in numbers and a passcode are provided for access.

What will OPKO management cover on the February 26, 2026 earnings conference call?

Management will present a business update, review operating and financial results and outline financial guidance for full-year 2025. According to the company, the discussion will include commentary from senior management during the live webcast and call.

Is pre-registration required to access OPKO (OPK) earnings call on February 26, 2026, and what are the benefits?

Pre-registration is encouraged but not required; pre-registered callers receive a unique PIN for immediate access. According to the company, PIN holders bypass the live operator and can still register at any time, even after call start.

Where can I find the OPKO (OPK) webcast and investor materials for the February 26, 2026 results?

The live webcast and replay will be available on OPKO’s Investor Relations page and linked webcast pages. According to the company, related presentation materials and the audio webcast will be accessible to investors during and after the call.